CooperVision® Expands MiSight® 1 day to Cover Nearly 100% of Spherical Prescriptions for Children with Myopia

Expanded Range of up to -10.00D Makes Myopia Control a Possibility for More Children Than Ever Before

SYDNEY, AUSTRALIA., JULY 20, 2022—CooperVision today announced that its MiSight® 1 day contact lenses are now available in higher prescriptions. The expanded range—covering -0.25D to -10.00D (0.50D steps after -6.00D)— means that MiSight® 1 day covers 99.97% of prescriptions for Asian children – and 99.97% for Caucasian children – who have myopia and less than 1D of astigmatism. The diopter extension for this innovative, specially designed lens will allow even more children to benefit from myopia management.

MiSight® 1 day contact lenses are backed by the longest-running soft contact lens study among children. The clinical trial has proven that MiSight® 1 day works for nearly all children with myopia, cuts myopia progression by half, works at any age a child starts treatment works for as long as the child wears them and that myopia control benefits from MiSight® 1 day are retained after treatment.

With myopia on the rise globally, an increasing number of children may require the higher prescriptions that MiSight® 1 day lenses will offer.

To read the full article, please click here